Navigation Links
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Date:1/28/2008

SAN DIEGO, Jan. 28 /PRNewswire/ -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Using its proprietary Ribosomal RNA Biogenesis Inhibition Technology (RABIT(TM)) to design molecules that combat drug-resistant forms of cancer, Cylene has created multiple product candidates in different stages of development. Cylene's most advanced cancer agent, quarfloxin (CX-3543), is a ribosomal RNA Biogenesis Inhibitor (RBI) in Phase II clinical development in patients having chronic lymphocytic leukemia and in late-stage Phase I development in patients having solid tumors. More information can be found at http://www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
6. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
7. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
8. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
9. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
10. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... Diego, CA (PRWEB) , ... May 20, 2017 ... ... support tool that helps avoid the lengthy trial and error process by finding ... patients. It can also strengthen the doctor-patient relationship through a personalized approach ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The ... disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, is ... UDIs and Traceability for Medical Devices conference in Brussels, Belgium. , Crowley played ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):